Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SCHU 3259/1-1)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH094759, R01MH094757, K01MH102415)
Received: 16 July 2019
Accepted: 22 May 2020
First Online: 6 July 2020
: B.O.R. has funding from Wounded Warrior Project, Department of Defense Clinical Trial Grant No.W81XWH-10-1-1045, National Institute of Mental Health grant no. 1R01MH094757-01 and McCormick Foundation. B.O.R. also receives royalties from Oxford University Press, Guilford, APPI and Emory University and received advisory board payments from Genentech, Jazz Pharmaceuticals, Sophren, Nobilis Therapeutics, Neuronetics and Aptinyx. C.R.M. serves on the scientific advisory board and has equity in Receptor Life Sciences. He also serves on the PTSD advisory board for Otsuka Pharmaceutical. He receives support from the National Institute on Alcohol Abuse and Alcoholism, National Institute of Mental Health, Department of Defense, US Army Congressionally Directed Medical Research Program, the Steven & Alexander Cohen Foundation, Cohen Veterans Bioscience, Cohen Veterans Network, Home Depot Foundation, McCormick Foundation, Robin Hood Foundation and the City of New York. C.B.N. discloses the following: research/grants from National Institutes of Health and Stanley Medical Research Institute; consulting (last three years) at Xhale, Takeda, Taisho Pharmaceutical Inc., Bracket (Clintara), Fortress Biotech, Sunovion Pharmaceuticals Inc., Sumitomo Dainippon Pharma, Janssen Research & Development LLC, Magstim, Inc., Navitor Pharmaceuticals, Inc., TC MSO, Inc. and Intra-Cellular Therapies, Inc.; stockholder of Xhale, Celgene, Seattle Genetics, Abbvie, OPKO Health, Inc., Antares, BI Gen Holdings, Inc., Corcept Therapeutics Pharmaceuticals Company, TC MSO, Inc. and Trends in Pharma Development, LLC; scientific advisory boards of American Foundation for Suicide Prevention (AFSP), Brain and Behavior Research Foundation, Xhale, Anxiety Disorders Association of America (ADAA), Skyland Trail, Bracket (Clintara) and Laureate Institute for Brain Research Inc.; board of directors of AFSP, Gratitude America, ADAA and Xhale Smart, Inc.; income sources or equity of USD$10,000 or more from American Psychiatric Publishing, Xhale, Bracket (Clintara), CME Outfitters, Takeda, Intra-Cellular Therapies, Inc., Magstim and EMA Wellness; patents for the method and devices for transdermal delivery of lithium (US 6,375,990B1), the method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2) and compounds, compositions, methods of synthesis and methods of treatment (CRF receptor binding ligand) (US 8,551,996 B2). K.J.R. performs consulting for Janssen, Verily, Alkermes and Biogen, Inc. on matters unrelated to this manuscript. I.R.G.-L. receives salary and stock options from AiCure. All other authors declare no competing interests.